Proteomic analysis of peripheral natural killer cells in primary central nervous system lymphoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054669

Enrollment

Unknown

Registered

2021-12-23

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma

Interventions

Primary central nervous system lymphoma group:None

Normal group:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; male or female; 2. Diagnosed as primary central nervous system lymphoma; 3. Those who understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are acute infections that require immediate intervention, including pneumonia, acute pyelonephritis, skin and soft tissue infections, and bloodstream infections; 2. Received PD-1/PD-L1 immunotherapy or other cellular immunotherapy; 3. Critically ill patients with unstable hemodynamics; 4. Presence of autoimmune disease.

Design outcomes

Primary

Measure	Time frame
Peripheral natural killer cells;	—

Countries

China

Contacts

Public ContactLin Zhiguang

Huashan Hospital Affiliated to Fudan University

zhiguang_lin@163.com+86 13917929043

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026